Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Ezetimibe
Cat. No.:
0225LY-0524
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Ezetimibe functions as a dietary cholesterol absorption inhibitor, effectively lowering overall cholesterol levels.
Synonym:
SCH 58235; 163222-33-1; (3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one; 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-
CAS No.:
163222-33-1
Compound CID:
150311
Formula:
C24H21F2NO3
Formula Weight:
409.43
Specification
Relative Density:
1.334 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Ezetimibe can be used in lipid metabolism research to study the selective inhibition of cholesterol absorption in the small intestine.
Library Information
Target:
NPC1L1; Nrf2
Receptor:
Keap1-Nrf2; NPC1L1; Sterol O-acyltransferase
Pathways:
Autophagy; Immunology/Inflammation; Membrane transporter/Ion channel
Plate Number:
AOCL-7
Plate Location:
g7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
260 mg/mL; 635.03 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
75 mg/mL; 183.18 mM
